admin

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 3, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits including viral gene elimination, today announced that

- PBGENE-HBV is the only drug modality designed to target the root cause of disease by eliminating cccDNA and inactivating integrated HBV - Clinical trial applications submitted for the first gene editing approach for chronic hepatitis B - Final clinical candidate safety data and plans for the

- Murray Abramson , MD, MPH appointed as Senior Vice President, Head of Clinical Development- - John Fry appointed as Strategic Clinical Advisor, Hepatitis - - Alan List , MD, Chief Medical Officer to Retire and Assume Role as Clinical Consultant as part of Precision’s Scientific Advisory Board -

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 4, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene

-- Payment includes $9.75 million cash and $3.25 million in Imugene Limited ordinary shares-- --The addition of this cash further reinforces Precision’s expected cash runway into the second half of 2026-- DURHAM, N.C. --(BUSINESS WIRE)--Sep. 3, 2024-- Precision BioSciences, Inc.

- Out licensed allogeneic CAR T azer-cel receives IND clearance from U.S. FDA DURHAM, N.C. --(BUSINESS WIRE)--Aug. 9, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for

- Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski ,

DURHAM, N.C. --(BUSINESS WIRE)--Jul. 31, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

DURHAM, N.C. --(BUSINESS WIRE)--Jul. 29, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2024

DURHAM, N.C. --(BUSINESS WIRE)--Jul. 8, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, today announced that the company will present at the upcoming JonesTrading

DURHAM, N.C. --(BUSINESS WIRE)--Jul. 1, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 27, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 20, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

- PBGENE-HBV specifically cuts HBV DNA without impacting the human genome - PBGENE-HBV was well tolerated across multiple administrations with no off-target editing observed - Preclinical safety data supports advancement of PBGENE-HBV to clinical trials as a potentially curative, finite treatment

DURHAM, N.C. --(BUSINESS WIRE)--May 30, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,